Cleared Traditional

LOBO Vascular Occlusion System (models LOBO-7 and LOBO-9) (K220383) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K220383 · Okami Medical · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2022
Decision
78d
Days
Class 2
Risk

K220383 is an FDA 510(k) clearance for the LOBO Vascular Occlusion System (models LOBO-7 and LOBO-9). Classified as Device, Vascular, For Promoting Embolization (product code KRD), Class II - Special Controls.

Submitted by Okami Medical (Aliso Viejo, US). The FDA issued a Cleared decision on April 29, 2022 after a review of 78 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.3300 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Okami Medical devices

Submission Details

510(k) Number K220383 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 10, 2022
Decision Date April 29, 2022
Days to Decision 78 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
47d faster than avg
Panel avg: 125d · This submission: 78d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KRD Device, Vascular, For Promoting Embolization
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.3300
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - KRD Device, Vascular, For Promoting Embolization

All 70
Devices cleared under the same product code (KRD) and FDA review panel - the closest regulatory comparables to K220383.
AZUR HydroPack 18 (45-880005
K223050 · MicroVention, Inc. · Dec 2022
Easi-Vue embolic microspheres System
K220567 · Abk Biomedical, Inc. · Sep 2022
GEM
K213385 · Obsidio, Inc. · Jul 2022
EMBOLD Fibered Detachable Coil System
K213398 · Boston Scientific Corporation · Apr 2022
Prestige Coil System
K220699 · Bait USA, LLC · Apr 2022
Solus Gold Embolization Device
K213200 · Artio Medical, Inc. · Mar 2022